<?xml version="1.0" encoding="UTF-8"?>
<p id="p0165">Currently, there is no clinically available drug or therapeutics endorsed by the U.S. FDA to prevent or contain COVID-19. The on-going clinical management for COVID-19 includes disease prevention (use of some clinically approved anti-viral drugs, hydroxychloroquine, immunosuppressant drugs), and supportive care in hospitals, including oxygen and ventilation support [
 <xref rid="bb0055" ref-type="bibr">11</xref>,
 <xref rid="bb0235" ref-type="bibr">47</xref>,
 <xref rid="bb0240" ref-type="bibr">48</xref>,
 <xref rid="bb0425" ref-type="bibr">85</xref>]. The quest for efficient treatment is proceeding with numerous investigations ongoing across the world. Recently, the USFDA has authorized the emergency use of remdesivir in severely ill hospitalized patients as this drug has been shown to fasten the recovery rate and is associated with less mortality rate ([
 <xref rid="bb0430" ref-type="bibr">86</xref>] issues emergency-use-authorization-potential-covid-19-treatment). In addition, Indian authorities (Drug Controller General of India) have approved oral antiviral drug favipiravir to treat mild to moderate COVID-19 [
 <xref rid="bb0435" ref-type="bibr">87</xref>].The list of repurposed drugs with completed clinical trials and a list of various potential repurposed drugs currently in clinical trials has been summarized in 
 <xref rid="t0005" ref-type="table">Table 1</xref> and 
 <xref rid="t0010" ref-type="table">Table 2</xref> , respectively [
 <xref rid="bb0425" ref-type="bibr">85</xref>,
 <xref rid="bb0440" ref-type="bibr">88</xref>].
</p>
